Bangkok Dusit Medical Services Public Company Limited(BDMS.BK)
No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THBm | 68,074 | 74,451 | 91,934 | 100,853 | 107,867 | 111,507 | N/A | N/A |
| Operating profit | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | THBm | 7,214 | 7,936 | 12,606 | 14,375 | 15,987 | 15,848 | N/A | N/A |
| EPS reported | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Bangkok Dusit Medical Services Public Company Limited (BDMS) functions as a prominent healthcare conglomerate, with its subsidiaries primarily engaged in operating and owning hospitals. The company oversees a portfolio of six major hospital networks, specifically the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital Group, and Royal Hospital Group. Beyond providing extensive medical treatment, BDMS also offers holistic clinical wellness programs. Its diversified business interests extend to hospitality, managing hotels and restaurants, as well as retailing health and beauty products. The company provides a broad spectrum of specialized services, including laboratory testing, advanced genome sequencing, skin and aesthetic telemedicine, and air medical transportation. Additionally, BDMS delivers business-centric services such as accounting, investment management, information technology, training, various insurance solutions (including health insurance and brokerage), and property and asset management. Its operations further encompass pharmaceutical manufacturing and distribution, e-commerce, and real estate ventures. BDMS maintains a significant presence with 47 hospitals operating across Thailand and Cambodia. The company was established in 1969 and is headquartered in Bangkok, Thailand.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Bangkok Dusit Medical Services Public Company Limited (BDMS) functions as a prominent healthcare conglomerate, with its subsidiaries primarily engaged in operating and owning hospitals. The company oversees a portfolio of six major hospital networks, specifically the Bangkok Hospital Group, Samitivej Hospital Group, BNH Hospital, Phyathai Hospital Group, Paolo Hospital Group, and Royal Hospital Group. Beyond providing extensive medical treatment, BDMS also offers holistic clinical wellness programs. Its diversified business interests extend to hospitality, managing hotels and restaurants, as well as retailing health and beauty products. The company provides a broad spectrum of specialized services, including laboratory testing, advanced genome sequencing, skin and aesthetic telemedicine, and air medical transportation. Additionally, BDMS delivers business-centric services such as accounting, investment management, information technology, training, various insurance solutions (including health insurance and brokerage), and property and asset management. Its operations further encompass pharmaceutical manufacturing and distribution, e-commerce, and real estate ventures. BDMS maintains a significant presence with 47 hospitals operating across Thailand and Cambodia. The company was established in 1969 and is headquartered in Bangkok, Thailand.
